A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2

Mona O. Mohsen*, Ina Balke, Simon Zinkhan, Villija Zeltina, Xuelan Liu, Xinyue Chang, Pascal S. Krenger, Kevin Plattner, Zahra Gharailoo, Anne Cathrine S. Vogt, Gilles Augusto, Marianne Zwicker, Salony Roongta, Dominik A. Rothen, Romano Josi, Joana J.da Costa, Jan M. Sobczak, Aleksandra Nonic, Lee Anne Brand, Katja NussByron Martina, Daniel E. Speiser, Thomas Kündig, Gary T. Jennings, Senta M. Walton, Monique Vogel, Andris Zeltins, Martin F. Bachmann

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)
12 Downloads (Pure)


Background: SARS-CoV-2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lock-downs, wearing masks, and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or adenoviruses, has greatly added to our ability to keep the virus at bay; again, however, in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for long-term control of SARS-CoV-2 would be inexpensive production at large scale, ability to make multiple booster injections, and long-term stability at 4℃. Methods: Here, we describe such a vaccine candidate, consisting of the SARS-CoV-2 receptor-binding motif (RBM) grafted genetically onto the surface of the immunologically optimized cucumber mosaic virus, called CuMVTT-RBM. Results: Using bacterial fermentation and continuous flow centrifugation for purification, the yield of the production process is estimated to be >2.5 million doses per 1000-litre fermenter run. We demonstrate that the candidate vaccine is highly immunogenic in mice and rabbits and induces more high avidity antibodies compared to convalescent human sera. The induced antibodies are more cross-reactive to mutant RBDs of variants of concern (VoC). Furthermore, antibody responses are neutralizing and long-lived. In addition, the vaccine candidate was stable for at least 14 months at 4℃. Conclusion: Thus, the here presented VLP-based vaccine may be a good candidate for use as conventional vaccine in the long term.

Original languageEnglish
Pages (from-to)243-257
Number of pages15
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number1
Early online date8 Sept 2021
Publication statusPublished - Jan 2022

Bibliographical note

Funding Information:
This work was supported by Saiba AG and Inselspital Bern. We thank PD Dr. AlexanderEggel and Dr. Daniel Brigger for providing wildtype RBD protein.

Publisher Copyright:
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.


Dive into the research topics of 'A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2'. Together they form a unique fingerprint.

Cite this